Free Trial
→ Strange: Why is Amazon suddenly yielding 39.70%? (From Investors Alley) (Ad) Free IONS Stock Alerts

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

Ionis Pharmaceuticals logo
$34.34 -2.89 (-7.76%)
(As of 11/15/2024 ET)
Compare

Ionis Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 19 Analyst Ratings
Sell
1
Hold
5
Buy
13

Based on 19 Wall Street analysts who have issued ratings for Ionis Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 1 has given a sell rating, 5 have given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for IONS.

Consensus Price Target

$60.65
76.61% Upside
According to the 19 analysts' twelve-month price targets for Ionis Pharmaceuticals, the average price target is $60.65. The highest price target for IONS is $77.00, while the lowest price target for IONS is $37.00. The average price target represents a forecasted upside of 76.61% from the current price of $34.34.
Get the Latest News and Ratings for IONS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Ionis Pharmaceuticals and its competitors.

Sign Up

IONS Analyst Ratings Over Time

TypeCurrent Forecast
11/18/23 to 11/17/24		1 Month Ago
10/19/23 to 10/18/24		3 Months Ago
8/20/23 to 8/19/24		1 Year Ago
11/18/22 to 11/18/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
6 Buy rating(s)
Hold
5 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$60.65$60.28$60.68$48.23
Forecasted Upside76.61% Upside51.91% Upside27.38% Upside-1.51% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold

IONS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IONS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Ionis Pharmaceuticals Stock vs. The Competition

TypeIonis PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.68
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside76.61% Upside28,534.41% Upside9.87% Upside
News Sentiment Rating
Neutral News

See Recent IONS News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/14/2024Piper Sandler
2 of 5 stars		 Lower TargetOverweight ➝ Overweight$65.00 ➝ $62.00+65.33%
11/7/2024Wells Fargo & Company
3 of 5 stars		 Lower TargetOverweight ➝ Overweight$82.00 ➝ $77.00+95.38%
11/7/2024Needham & Company LLC
3 of 5 stars		 Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00+53.69%
10/9/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$70.00 ➝ $65.00+69.40%
9/26/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.00+70.77%
8/26/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral ➝ Neutral$50.00 ➝ $55.00+17.25%
8/2/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		S. Richter
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetSell ➝ Sell$33.00 ➝ $37.00-24.40%
8/2/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetEqual Weight ➝ Equal Weight$45.00 ➝ $51.00+4.74%
8/2/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		K. Biliouris
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Market Perform$67.00 ➝ $60.00+16.91%
7/24/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. Foroohar
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeHold ➝ Strong-Buy
7/24/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeMarket Perform ➝ Outperform$53.00 ➝ $62.00+22.94%
7/23/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$54.00 ➝ $59.00+16.79%
7/23/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$67.00 ➝ $68.00+34.36%
7/16/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageUnderperform ➝ Buy$29.00 ➝ $75.00+57.66%
6/27/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetHold ➝ Hold$50.00 ➝ $53.00+11.11%
6/14/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating		W. Pickering
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeUnderperform ➝ Market Perform$44.00+7.00%
4/10/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradePeer Perform ➝ Outperform$58.00+35.42%
4/9/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform
4/9/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$72.00 ➝ $75.00+77.56%
11/3/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetEqual Weight ➝ Equal Weight$45.00 ➝ $48.00+9.76%
9/28/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageStrong-Buy$63.00+36.19%
7/31/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Buy$36.00 ➝ $60.00+50.79%
5/4/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMaintains
2/23/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$34.00 ➝ $27.00-26.63%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:59 AM ET.


IONS Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Ionis Pharmaceuticals is $60.65, with a high forecast of $77.00 and a low forecast of $37.00.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There is currently 1 sell rating, 5 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IONS shares.

According to analysts, Ionis Pharmaceuticals's stock has a predicted upside of 76.61% based on their 12-month stock forecasts.

Ionis Pharmaceuticals has been rated by research analysts at Guggenheim, JPMorgan Chase & Co., Needham & Company LLC, Piper Sandler, Royal Bank of Canada, and Wells Fargo & Company in the past 90 days.

Analysts like Ionis Pharmaceuticals less than other "medical" companies. The consensus rating score for Ionis Pharmaceuticals is 2.68 while the average consensus rating score for "medical" companies is 2.80. Learn more on how IONS compares to other companies.

Related Companies
Today's Ratings
Top Rated Stocks
More Ratings Tools

This page (NASDAQ:IONS) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...
Colonial Metals | Sponsored
Unveiled: NVIDIA’s "Secret Royalty" Program
Did you know that there's an investment that will give you the opportunity to collect "royalties" every time N...
Behind the Markets | Sponsored